<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411684</url>
  </required_header>
  <id_info>
    <org_study_id>2914-005</org_study_id>
    <nct_id>NCT00411684</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CDB-2914 for Emergency Contraception</brief_title>
  <official_title>A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CDB-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Sex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRA Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HRA Pharma</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing
      pregnancy when taken 3 to 5 days after unprotected sexual intercourse.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevented fraction (number of prevented pregnancies divided by the number of expected pregnancies)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on menstrual bleeding patterns</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequencies of subjects with treatment emergent adverse events</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1320</enrollment>
  <condition>Emergency Contraception</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDB-2914</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or more

          -  Menstruating women with regular menstrual cycle between 24 and 35 days and
             intra-individual variations less than or equal to 5 days

          -  Request emergency contraception between 48 hours and 120 hours after unprotected
             intercourse as defined by lack of contraceptive use, or condom breakage (including
             condoms lubricated with spermicide) or other barrier contraceptive method failure

          -  No current use of hormonal contraception and having had at least one complete
             menstrual cycle (2 menses) since having stopped hormonal contraception

          -  For women with a recent history of Depo Provera use, the most recent injection must
             have been at least 9 months before study entry and followed by at least one complete
             menstrual cycle (2 menses)

          -  Willing to not use hormonal methods of contraception until study completion

          -  At least one complete menstrual cycle (2 menses) post delivery, miscarriage or
             abortion

          -  Able to provide informed consent in English

          -  Give voluntary, written informed consent, and agree to observe all study requirements
             (the subject needs to be available for follow-up over the next 6 weeks)

          -  Willing to abstain from further acts of unprotected intercourse during participation
             in the study and until pregnancy status has been ascertained

        Exclusion Criteria:

          -  One or more acts of one unprotected intercourse more than 120 hours before requesting
             emergency contraception in the current cycle

          -  All acts of unprotected intercourse (in the current cycle) within 48 hours of
             presentation

          -  Currently pregnant as confirmed by positive HSUP test performed at screening

          -  Currently breast-feeding

          -  Current use of hormonal contraception

          -  Use of hormonal emergency contraception since last menstrual period

          -  Current use of IUD

          -  Tubal ligation

          -  Partner with a vasectomy

          -  Unsure about the date of the last menstrual period

          -  Severe asthma insufficiently controlled by oral glucocorticoid

          -  Currently enrolled in any other trial of an investigational medicine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Fine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Planned Parenthood of Houston and Southeast Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood of Mar Monte</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of the Rocky Mountains</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Greater Miami, Palm Beach and Treasure Cost</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of South Palm Beach, Pembroke Pines</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Indiana</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Greater Iowa</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood League of Massachusetts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Mid-Michigan Alliance</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Greater Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Columbia-Willamette</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of SE Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of the Texas Capital Region</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Houston and Southeast Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Association of Utah</name>
      <address>
        <city>Salt Lake</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Western Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol. 2010 Feb;115(2 Pt 1):257-63. doi: 10.1097/AOG.0b013e3181c8e2aa.</citation>
    <PMID>20093897</PMID>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2006</study_first_posted>
  <last_update_submitted>June 16, 2010</last_update_submitted>
  <last_update_submitted_qc>June 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

